Ultragenyx Pharmaceutical (RARE): EV/EBITDA Multiple

Public company logo of Ultragenyx Pharma (RARE)

The EV/EBITDA history of Ultragenyx Pharmaceutical (RARE) demonstrates stable demand for lifelong therapies for rare pathologies, with the current status equal to 0.00. Legal monopolies in niche markets are secured by orphan drug status, while the humanitarian focus of gene therapy ensures protection from geopolitical risks and trade conflicts.

Ultragenyx Pharma - RARE Company Value to EBITDA (period 11/23/2025 - 11/16/2026)

RARE (Ultragenyx Pharma): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company valuation:Ultragenyx Pharmaceutical (RARE)
Manufactured products of Ultragenyx Pharmaceutical Inc.

High debt loads for biopharmaceutical companies increase their vulnerability to market shocks, yet the colossal potential of Ultragenyx Pharmaceutical (RARE) in gene therapy and mRNA technologies creates a significant valuation foundation. By analyzing the company's dynamic EV/EBITDA metric, an investor compares the total enterprise value with operating profit before taxes and interest, determining the real value of assets relative to their ability to generate cash flow.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Company Value to EBITDA beamtx.com BEAM|Enterprise Value to EBITDA Ratio SRPT (Sarepta Therapeutics, Inc.)|TWST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x TXG|Enterprise Value to Operating Income Before Depreciation Ratio NTLA (Intellia)|Stoke Corp - EV/EBITDA Multiple|BLFS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WVE: EV/EBITDA Multiple|Company Value to EBITDA Maze Tx (MAZE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Corp)|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniqure.com (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx PLC MGTX|Business Value to Operating Income Before Depreciation RGNX|solidbio.com - EV/EBITDA Multiple|OCGN (Ocugen Pharma) - Enterprise Value to Operating Income Before Depreciation|PACB: EV/EBITDA Multiple|Benitec Biopharma (BNTC) - EV/EBITDA Multiple|DSGN (Design Therapeutics Inc) - EV/EBITDA Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|FDMT - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc